PAI Life Sciences Doses First Healthy Volunteer in Schistosomiasis Vaccine Clinical Trial
PAI Life Sciences, a biotechnology company specializing in translational research for neglected tropical diseases, today announced the dosing of the first healthy volunteer in a clinical trial of SchistoShield®, the company’s preventive vaccine against schistosomiasis, a major tropical disease threatening nearly 1 billion people in 79 countries with more than 260 million people currently infected. Darrick Carter, professor of global health, was mentioned.